MITHRA ANNOUNCES 2017 FINANCIAL CALENDAR

PRESS RELEASE

Liège, Belgium 11 January 2017 - Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women's health, today announces its financial calendar for 2017.

  • 2 March 2017: Full Year Results 2016

  • 18 April 2017: Annual Report 2016

  • 18 May 2017: Annual General Meeting 2017

  • 12 September 2017: Half Year Results 2017 This schedule is indicative and subject to change.

The calendar is also available on Mithra's Investor website: investors.mithra.com.

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart, is a Euronext listed pharmaceutical company (MITRA) focused on Women's Health. Mithra's mission is to improve every stage of women's life with innovative and accessible pharmaceutical solutions. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical solutions in four therapeutic fields of women's health: fertility and contraception, menopause and osteoporosis, gynecological infections and female cancers.

Mithra has an approximate headcount of 141 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

For more information, please contact:

Press

Julie Dessart

Chief Communication Officer

+32 4 349 28 22 / +32 475 86 41 75

press@mithra.com

Investor Relations

François Fornieri, CEO

+32 4 349 28 22

investorrelations@mithra.com

Consilium Strategic Communications Jonathan Birt, Sue Stuart, Hendrik Thysmithra@consilium-comms.com

+44 2 037 095 700

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward- looking statements". These forward-looking statements can be identified by the use of forward- looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com

Mithra Pharmaceuticals SA published this content on 11 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 11 January 2017 18:33:08 UTC.

Original documenthttp://investors.mithra.com/wp-content/uploads/2017/01/2017-01-11-Financial-Calendar-2017-en.pdf

Public permalinkhttp://www.publicnow.com/view/4ECC29DEA89137DF437C30C2DC678F7A96F818E1